Biogen (NASDAQ:BIIB) Price Target Raised to $260.00

Biogen (NASDAQ:BIIB) had its target price hoisted by TD Cowen from $250.00 to $260.00 in a report released on Thursday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other research analysts also recently commented on BIIB. Morgan Stanley lifted their price target on Biogen from $222.00 to $231.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. Zacks Research raised shares of Biogen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. Canaccord Genuity Group increased their price objective on Biogen from $245.00 to $248.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. UBS Group lifted their target price on shares of Biogen from $270.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Biogen in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $251.00.

Biogen Price Performance

NASDAQ BIIB opened at $253.62 on Thursday. The stock’s 50-day moving average is $227.08 and its two-hundred day moving average is $201.04. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.26. Biogen has a fifty-two week low of $146.52 and a fifty-two week high of $258.78. The firm has a market cap of $37.49 billion, a P/E ratio of 108.38, a price-to-earnings-growth ratio of 2.97 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The firm had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.63 billion. During the same period in the previous year, the company earned $4.81 EPS. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, analysts anticipate that Biogen will post 12.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Biogen

A number of hedge funds and other institutional investors have recently made changes to their positions in BIIB. BlackRock Inc. bought a new position in Biogen during the second quarter worth about $3,453,878,000. Primecap Management Co. CA acquired a new position in Biogen during the 2nd quarter worth approximately $3,274,304,000. Wellington Management Group LLP grew its position in Biogen by 5.3% in the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock valued at $673,560,000 after purchasing an additional 155,828 shares in the last quarter. Amundi grew its holdings in shares of Biogen by 91.8% in the 2nd quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock valued at $327,727,000 after acquiring an additional 726,004 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Biogen during the 2nd quarter worth approximately $322,640,000. 87.93% of the stock is owned by institutional investors.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.